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Background/Aims: DA-6034 has anti-inflammatory activi-
ties and exhibits cytoprotective effects in acute gastric injury 
models. However, explanations for the protective effects of 
DA-6034 on intestinal permeability are limited. This study 
sought to investigate the effect of DA-6034 on intestinal per-
meability in an indomethacin-induced small intestinal injury 
model and its protective effect against small intestinal injury. 
Methods: Rats in the treatment group received DA-6034 
from days 0 to 2 and indomethacin from days 1 to 2. Rats 
in the control group received indomethacin from days 1 to 
2. On the fourth day, the small intestines were examined to 
compare the severity of inflammation. Intestinal permeability 
was evaluated by using fluorescein isothiocyanate-labeled 
dextran. Western blotting was performed to confirm the asso-
ciation between DA-6034 and the extracellular signal-regulat-
ed kinase (ERK) pathway. Results: The inflammation scores 
in the treatment group were lower than those in the control 
group, but the difference was statistically insignificant. Hem-
orrhagic lesions in the treatment group were broader than 
those in the control group, but the difference was statistically 
insignificant. Intestinal permeability was lower in the treat-
ment group than in the control group. DA-6034 enhanced ex-
tracellular signal-regulated kinase expression, and intestinal 
permeability was negatively correlated with ERK expression. 
Conclusions: DA-6034 may decrease intestinal permeabil-
ity in an indomethacin-induced intestinal injury model via 
the ERK pathway. (Gut Liver 2016;10:406-411)
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INTRODUCTION
The epithelial layer of the gastrointestinal tract serves as one 
of the primary interfaces with the outside world. The mucosal 
surface of the intestinal epithelium is in constant contact with 
innumerable microbes and their metabolites. The leaky gut 
syndrome has received increasing attention in the recent past. 
The leaky syndrome is simply a phenomenon of passage of li-
popolysaccharide or toxins of gram-negative bacteria into the 
blood stream due to disintegration of intestinal mucosa, which 
causes bacteremia, endotoxemia, and systemic inflammation. 
Increased intestinal permeability is known to be associated with 
several circumstances; the leaky gut syndrome is associated 
with the long-term use of nonsteroidal anti-inflammatory drug 
(NSAID), which is an essential pathogenesis of inflammatory 
bowel disease (IBD) and irritable bowel syndrome (IBS).1-4 It also 
contributes to the expression and progression of the alcoholic 
liver disease and chronic liver disease as well as congestive 
heart failure.5,6 Moreover, the leaky gut syndrome has been 
viewed as an important pathogenesis of diabetic mellitus and 
obesity in relation to insulin resistance.7,8
To treat and prevent the increase of intestinal permeability, 
some studies have been performed. While rebamipide, probiot-
ics, and proton pump inhibitor have been studied, they eluci-
dated protective effects on intestinal permeability.9-11 DA6034, 
which is an active derivative of Artemisia extracts in plants, 
exhibited not only a gastroprotective effect in several gastric in-
jury models, but also indicated anti-inflammatory effect by in-
hibiting nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-kB).12,13 However, there are only limited explanations 
about the protective effects of DA-6034 on intestinal perme-
ability. The study aims at evaluating the effect of DA-6034 on 
intestinal permeability, using fluorescein isothiocyanate-labeled 
dextran. It also compares the inflammation severity of the treat-
ment group with that of the control group using hematoxylin 
and eosin (H&E) stain. The Western blot analysis was also car-
ried out to confirm the association of DA-6034 with extracel-
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lular signal-regulated kinase (ERK) pathway in the prevention of 
the leaky gut syndrome.
MATERIALS AND METHODS
1. Animal and reagent
Orient Bio, Korea provided 36 Sprague-Dawley rats, weighing 
250 g at 6 weeks. The rats were housed in animal facilities with 
50%±5% humidity, 23oC±2oC temperature and a 12:12-hour 
light-dark cycle and raised with samtako during the experiment. 
All experiments were performed in accordance with the institu-
tional and national guidelines for the care and use of laboratory 
animals approved by the Ethics Committee of Hanyang Univer-
sity (HY-IACUC-10-020). 
2. Experimental protocol
Rats were randomly divided into two groups namely; DA-
6034/indomethacin and indomethacin group. In the treatment 
group, rats were orally administered DA-6034 30 mg/kg q 12 
hours from the day 0 to day 2 with indomethacin 15 mg/kg q 
12 hours from day 1 to day 2. In the control group, rats were 
administered only indomethacin 15 mg/kg q 12 hours from day 
1 to day 2. On day 3, rats were dissected and small intestines 
were removed immediately (Fig. 1).
3. Intestinal permeability
In order to measure intestinal barrier permeability, rats were 
gavaged with a permeability tracer, FITC-labeled dextran (6 
mg/100 g body weight of FITC-labeled dextran, mol wt. 4,000; 
Sigma-Aldrich, St. Louis, MO, USA) on day 3. While food and 
water were withdrawn 4 hours before the gavage. Four hours 
after gavage, blood was withdrawn by cardiac puncture 4 hours 
after the gavage. Fluorescence intensity of the serum samples 
was measured using a Victor 3 spectrophotometer (excita-
tion 490 nm, emission 525 nm, Cytofluor 2300; PerkinElmer, 
Waltham, MA, USA; Waters Chromatography). The FITC-
dextran concentrations were determined from standard curves 
generated by serial dilution of FITC-dextran. Permeability was 
calculated by the linear regression of sample fluorescence.14
4. Histology
Histologic examination was carried out on small intestine 
segments removed from rats of each group. Intestinal segments 
were immediately injected with 10% formalin and left in the 
same fixative solution. After 30 minutes, they were opened 
along the antimesenteric border, cleaned of fecal content and 
fixed in a 10% formalin for 24 hours. Six sections were ran-
domly chosen from each intestinal segment and processed into 
paraffin. Serial paraffin sections (4 μm) were then prepared and 
stained with H&E. An independent observer without previous 
knowledge of the treatment assessed the histologic damage. The 
damage was estimated microscopically not only as the sum of 
the mucosal score but also as the indices of inflammation. The 
mucosal score was rated on a 4-point scale (0 to 3) according 
to the criteria established by Chiu et al.15 with modifications. 
Moreover, the extent of the hemorrhagic lesion was calculated 
as well (Table 1).
5. Western blotting analysis
To elucidate the mechanism of DA-6034-induced cytoprotec-
tive effect, protein expression was examined using the immu-
noblotting technique. It assumes that the ERK pathway is related 
- Indomethacin (15 mg/kg) q 12 hours
- Eupatilin (30 mg/kg bid)
Day 0 (fasting) Day 1 Day 2 Day 3
Treatment group
Control group
Eupatilin Indomethacin & eupatilin Indomethacin & eupatilin
SacrificeIndomethacin onlyIndomethacin only
Sacrifice
Fig. 1. Rats were randomly divided 
into two groups (DA-6034/indometh-
acin and indomethacin groups). In 
the treatment group, rats were orally 
administered DA-6034 30 mg/kg q 
12 hours from day 0 to day 2 with 
indomethacin 15 mg/kg q 12 hours 
from day 1 to day 2. In the control 
group, rats were administered only 
indomethacin 15 mg/kg q 12 hours 
from day 1 to day 2. On day 3, the 
rats were sacrificed, and their small 
intestines were removed immediately.
bid, twice a day.
Table 1. Inflammation Score and Histologic Findings
Inflammation score Histologic finding
0 Absence of inflammatory reaction, ulceration or tissue destruction
1 Slight inflammatory reaction but no ulceration or tissue destruction
2 Moderate inflammatory infiltration with mild tissue destruction of villous, crypts but no ulceration
3 Intense inflammatory reaction, presence of ulceration and extensive tissue destruction
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to the preventive effect of intestinal permeability of DA-6034. 
The Western blot analysis was employed in confirming the hy-
pothesis. The tissue of small intestine was washed with 4 to 5 
mL of phosphate buffered saline, grinded with homogenizer and 
incubated for 10 minutes at 0oC. Then they were centrifuged 
for 10 minutes and supernatant was gathered. Total protein 
was acquired by using protein quantification solution (Bio-Rad 
Laboratories, Hercules, CA, USA). The total proteins were mixed 
with sodium dodecyl sulfate sample buffer (Tris-Cl [pH6.8] 100 
mM, glycerol 20%, bromophenol blue 0.2%, SDS 4%, dithioth-
reitol 200 mM) and boiled at 100oC for 10 minutes. The samples 
were then subjected to SDS-polyacrylamide gel and blotted 
onto a polyvinylidene fluoride membrane (Atto Corp., Tokyo, 
Japan). The membrane was blocked with Tris-buffered saline 
and Tween buffer (10 mM Tris, 150 mM NaCl, 0.1% Tween 20) 
at room temperature for 60 minutes. Western blotting analysis 
was carried out using p-ERK antibody, total form ERK antibody 
(Cell Signaling Technology Inc., Danvers, MA, USA) at 4oC 
overnight. After three washes with TBS-T, the membrane was 
incubated with anti-rabbit or anti-mouse IgG (IgG-HRP) (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature 
for 60 minutes. The signals were visualized using an enhanced 
chemiluminescence solution (Amersham, Buckinghamshire, UK), 
according to the manufacturer’s instructions.
6. Statistical analysis
The t-test was used to test for association among non-
categorical variables and correlation test was used to assess as-
sociation between ERK pathway and intestinal permeability. A 
p-value <0.05 was considered to indicate statistical significance. 
All statistical analyses were performed using the SPSS version 
18 software (SPSS Inc., Chicago, IL, USA)
RESULTS
1. Effect of DA-6034 on small bowel inflammation
When the severity of inflammation between two groups was 
compared macroscopically, the severity of necrosis and color 
change was more severe in the control group than treatment 
group. The damage was estimated microscopically as not only 
the sum of the mucosal score but also the indices of inflam-
mation. The inflammation score was lower in the treatment 
group, but it was not statistically significant (2.6±0.6 vs 2.9±0.3, 
p=0.11) (Fig. 2A). When the extent of hemorrhage was com-
pared, a hemorrhagic lesion in the treatment group was broader 
than that of the control group but was not statistically signifi-
cant (45.0±45.5 vs 43.0±33.8, p=0.88) (Fig. 2B).
2. Intestinal permeability 
Intestinal permeability evaluated by FITC-labeled dextran 
was lower in the treatment group compared to control group 
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Fig. 2. (A) The inflammation score in the treatment group was lower than in the control group, but the difference was statistically insignificant 
(2.6±0.6 vs 2.9±0.3, p=0.11). (B) The extent of the hemorrhagic lesions was broader in the treatment group, but the difference was not statistically 
significant (45.0±45.5 vs 43.0±33.8, p=0.88).
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Fig. 3. Intestinal permeability evaluated by using FITC-labeled dex-
tran was lower in the treatment group compared with the control 
group (16,204.2±13,832.1 vs 30,403.7±24,012.6, p<0.05). 
*p<0.05.
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(16,204.2±13,832.1 vs 30,403.7±24,012.6, p<0.05) (Fig. 3). 
3. Effect of DA-6034 on ERK phosphorylation
The densitometric assessment showed that pretreatment with 
DA-6034 before indomethacin increased the ERK expression 
(107.4±40.1 vs 64.2±20.4, p<0.05) (Fig. 4A). The expression of 
ERK pathway was more prominent in the treatment group com-
pared to that of the control group (Fig. 4B). As such, the intesti-
nal permeability was negatively correlated with density of ERK 
expression (r=-0.309, p=0.096) (Fig. 5). 
DISCUSSION
Long term use of NSAID is known to increase intestinal per-
meability by inhibiting oxidative phosphorylation in intestinal 
epithelium and by suppressing cyclooxygenase isoenzymes.4 
In patients with chronic liver disease, small intestinal bacterial 
overgrowth is associated with the increase of intestinal perme-
ability. In the pathogenesis of IBD, the bacterial translocation 
caused by the increase of intestinal permeability leads to chronic 
intestinal inflammation and eventually IBD. The intestinal per-
meability contributes to the IBS, obesity, and insulin resistance. 
With this clinical awareness, studies to treat those diseases by 
alleviating the increase in intestinal permeability are undergo-
ing in many perspectives. Probiotics showed an improving 
effect on intestinal permeability by alleviating small intestinal 
overgrowth in patients with chronic liver disease. Nonetheless, 
the anti-transforming growth factor blocker and prednisolone 
demonstrated an improving effect on intestinal permeability in 
IBD.3,16 Moreover, the 5-hydroxytryptamine receptor antagonist 
also alleviated intestinal inflammation by inhibiting inflamma-
tory cytokine, free radical production which were effective in 
preventing the increase of intestinal permeability.17
The DA-6034 exhibited a gastro-protective effect in several 
gastric injury models, which may result from increases in de-
fense factors, such as mucus secretion and endogenous prosta-
glandin E2 synthesis. It also showed anti-inflammatory effect 
by inhibiting NF-kB in colitis model, as such, it is expected to 
be effective in the treatment of the IBD.12,13 But DA-6034 effect 
on intestinal permeability remained unevaluated. This study 
showed the effect of DA-6034 treatment on intestinal permea-
bility, using FITC-labeled dextran, that the intestinal permeabil-
ity was lower in the treatment group compared to control group 
(16,204.2±13,832.1 vs 30,403.7±24,012.6, p<0.05), suggesting 
DA-6034 prevents the increase of intestinal permeability. In the 
histologic evaluation, the inflammation score in the treatment 
group was lower compared with that in the control group with 
little statistical significance (2.61±0.60 vs 2.88±0.33, p=0.11). 
The result did not show the significant histological protective 
effect of DA-6034 on intestinal damage.
Concerning the role of the ERK signaling pathway in epitheli-
al restitution, several studies have been conducted in which ac-
tivation of the ERK signaling pathway played a significant role 
in epithelial wound closure.18-20 We assumed ERK pathway may 
contribute to preventing increment of intestinal permeability. 
The ERK expression was compared in each group to determine 
whether ERK signaling pathway played a role in the underlying 
mechanism of DA-6034 by Western blot. The result showed that 
the intestinal permeability was lower in the treatment group 
compared to control group, ERK phosphorylation was enhanced 
in the treatment group, and intestinal permeability was nega-
tively correlated with ERK phosphorylation despite of statistical 
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Fig. 4. (A) The densitometric assessment showed that pretreatment 
with DA-6034 before indomethacin increased extracellular signal-
regulated kinase (ERK) expression (107.4±40.1 vs 64.2±20.4, p<0.05). 
(B) The expression of the ERK pathway was more prominent in the 
treatment group than in the control group.
*p<0.05.
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Fig. 5. Intestinal permeability was negatively correlated with the level 
of extracellular signal-regulated kinase (ERK) expression, suggesting 
that the ERK pathway is related to a protective effect on intestinal 
permeability (r=-0.309, p=0.096).
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insignificance. That implies ERK pathway takes a crucial role in 
preventing the increase of intestinal permeability when intesti-
nal mucosal becomes disintegrated by indomethacin.
It is suggested that an increase in the permeability of small 
intestinal mucosa was an important factor in the mechanism of 
NSAID-induced small intestinal injury. Increased intestinal per-
meability leads to large molecules contained in food substances, 
bile acids, pancreatic juice, bacteria and other toxins within the 
lumen passing through the intestinal epithelial barrier, causing 
intestinal inflammation and injury. Therefore, the change in 
small intestinal permeability could directly reflect small intesti-
nal mucosal integrity and barrier function and help to identify 
early damage to intestinal mucosa.9 In this study, however, im-
provement of intestinal permeability did not result in protection 
of intestinal mucosal damage. Though it has somewhat limited 
value for direct comparison since there were no report evaluat-
ing the effect of DA-6034 on NSAID-induced small intestinal 
damage with microscope, DA-6034 (30 mg/kg) is previously 
reported to have had protective effect on mucosal damage in 
dextran sulfate sodium-induced colitis model.13 Therefore, fur-
ther study with modification of treatment duration, such as two 
or three day additional treatment after indomethacin on the 
effectiveness of DA-6034 in the alleviation of small intestinal 
mucosal damage may be necessary. In conclusion, DA-6034 
shows possible role in prevention of the leaky gut syndrome in 
indomethacin-induced intestinal injury model by enhancing 
restitution of intestinal epithelial cells via ERK activation. And 
our results suggest DA-6034 could be a potential therapeutic 
drug for diseases associated with leaky gut syndrome, such as 
IBD, IBS, and obesity and so forth, by modifying intestinal per-
meability.
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